S. HOLTSCLAW-BERK

Clinical and microbiologic consequences of amikacin use during a 42-month period.

A. Verghese, S. Alvarez, S. Berk, 1986, Archives of internal medicine.

Phenotypic characteristics of Branhamella catarrhalis strains

L. Harvill, S. Berk, J. Soto-Hernández, 1989, Journal of clinical microbiology.

Nosocomial pneumococcal bacteremia.

S. Alvarez, C. Shell, J. Guarderas, 1986, Archives of internal medicine.

In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis

M. Jones, S. Alvarez, J. Guarderas, 1985, Antimicrobial Agents and Chemotherapy.

Selective medium with DNase test agar and a modified toluidine blue O technique for primary isolation of Branhamella catarrhalis in sputum

S. Berk, J. Soto-Hernández, S. Holtsclaw-Berk, 1988, Journal of clinical microbiology.

In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis

A. Verghese, S. Berk, F. Sarubbi, 1989, Antimicrobial Agents and Chemotherapy.